Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada.
Int J Lab Hematol. 2020 Dec;42(6):801-809. doi: 10.1111/ijlh.13302. Epub 2020 Aug 6.
Calibrated automated thrombograms (CAT) with platelet-poor (PPP) and platelet-rich plasma (PRP) have provided useful insights on bleeding disorders. We used CAT to assess thrombin generation (TG) in Quebec platelet disorder (QPD)-a bleeding disorder caused by a PLAU duplication mutation that increases platelet (but not plasma) urokinase plasminogen activator (uPA), leading to intraplatelet (but not systemic) plasmin generation that degrades α-granule proteins and causes platelet (but not plasma) factor V (FV) deficiency.
Calibrated automated thrombograms was used to test QPD (n = 7) and control (n = 22) PPP and PRP, with or without added tranexamic acid (TXA). TG endpoints were evaluated for relationships to platelet FV and uPA, plasma FV and tissue factor pathway inhibitor (TFPI) levels, and bleeding scores.
Quebec platelet disorder PPP TG was normal whereas QPD PRP had reduced endogenous thrombin potential and peak thrombin concentrations (P values < .01), proportionate to the platelet FV deficiency (R ≥ 0.81), but unrelated to platelet uPA, plasma FV, or bleeding scores. QPD TG abnormalities were not associated with TFPI abnormalities and were not reproduced by adding uPA to control PRP. TXA increased QPD and control PRP TG more than PPP TG, but it did not fully correct QPD PRP TG abnormalities or improve TG by plasminogen-deficient plasma.
Quebec platelet disorder results in a platelet-specific TG defect, proportionate to the loss of platelet FV, that is improved but not fully corrected by TXA. Our study provides an interesting example of why it is important to assess both PRP and PPP TG in bleeding disorders.
使用血小板缺乏(PPP)和富含血小板的血浆(PRP)的校准自动化血栓图(CAT)为出血性疾病提供了有用的见解。我们使用 CAT 评估了 Quebec 血小板障碍(QPD)患者的凝血酶生成(TG),QPD 是一种由 PLAU 重复突变引起的出血性疾病,该突变增加了血小板(但不是血浆)尿激酶纤溶酶原激活物(uPA),导致血小板内(但不是全身)纤溶酶生成,降解α-颗粒蛋白并导致血小板(但不是血浆)因子 V(FV)缺乏。
使用校准自动化血栓图测试 QPD(n=7)和对照(n=22)PPP 和 PRP,有无添加氨甲环酸(TXA)。评估 TG 终点与血小板 FV 和 uPA、血浆 FV 和组织因子途径抑制剂(TFPI)水平以及出血评分的关系。
QPD PPP TG 正常,而 QPD PRP 则表现出降低的内源性凝血酶潜能和最大凝血酶浓度(P 值均<0.01),与血小板 FV 缺乏成比例(R≥0.81),但与血小板 uPA、血浆 FV 或出血评分无关。QPD TG 异常与 TFPI 异常无关,且在向对照 PRP 中添加 uPA 时无法复制。TXA 增加了 QPD 和对照 PRP TG,超过了 PPP TG,但不能完全纠正 QPD PRP TG 异常或改善缺乏纤溶酶原的血浆中的 TG。
Quebec 血小板障碍导致血小板特异性 TG 缺陷,与血小板 FV 丧失成比例,TXA 可改善但不能完全纠正。我们的研究提供了一个有趣的例子,说明为什么在出血性疾病中评估 PRP 和 PPP TG 非常重要。